Marie Bosslett

1 week ago | dermatologytimes.com | Marie Bosslett

Global results from a recent survey have given clinical insights into the psychosocial impact hidradenitis suppurativa (HS) may have on patients across the world.1 “HS Uncovered” Burden of Disease Survey was created to help providers better understand patient journeys and perspectives with HS. The real-world, quantitative online survey included data from 656 patients.

1 week ago | dermatologytimes.com | Emma Andrus |Marie Bosslett

The US FDA announced today its approval of dupilumab (Dupixent; Regeneron Pharmaceuticals, Inc. and Sanofi) for adults with bullous pemphigoid (BP), marking the first and only targeted therapy for this patient population.1The approval is supported by positive data from the pivotal phase 2/3 LIBERTY-BP ADEPT study.2 The randomized, double-blind, placebo-controlled study assessed dupilumab in a cohort of 106 adults with moderate to severe BP over the course of 52 weeks.

1 week ago | dermatologytimes.com | Marie Bosslett

Data from the global Vitiligo and Life Impact Among International Communities (VALIANT) survey has revealed high rates of depression and depressive symptoms in patients with vitiligo.1 About 75% of surveyed patients had symptoms of depression.

1 week ago | dermatologytimes.com | Marie Bosslett

Positive retrospective study data has confirmed upadacitinib and abrocitinib's efficacy for moderate-to-severe atopic dermatitis (AD) in real-world settings.1 Safety and effectiveness have been proven in phase 3 clinical trials, but long-term, real-world results have been limited for these JAK inhibitors. For this trial, the AD database records of IRCCS Humanitas Research Hospital-Rozzano in Milan, Italy, were utilized. These electronic records were analyzed between January 2023 and December 2024.

1 week ago | dermatologytimes.com | Marie Bosslett |Mercedes E. Gonzalez |Mercedes González

“When I'm seeing a patient, an infant with atopic dermatitis (AD), I'd much prefer to have a conversation to discuss the side effect profile of roflumilast than having to discuss the side effect profile of a topical corticosteroid,” Mercedes E. Gonzalez, MD, told Dermatology Times.